Rybin, A. I.     Dynamics of survival in patients with ovarian cancer lll-IV degree [Text] = Динаміка виживання хворих на рак яєчників III-IV ступеня / A. I. Rybin, V. S. Svintsitsky // Вісник Вінницького нац. мед. ун-ту. - 2017. - Т. 21, № 1. Ч.2. - P294-297. - Bibliogr. at the end of the art. MeSH-головна: ЯИЧНИКОВ НОВООБРАЗОВАНИЯ -- OVARIAN NEOPLASMS (диагностика, смертность, терапия) ЛЕКАРСТВЕННАЯ ТЕРАПИЯ КОМБИНИРОВАННАЯ -- DRUG THERAPY, COMBINATION (использование, методы) ВЫЖИВАЕМОСТИ АНАЛИЗ -- SURVIVAL ANALYSIS АДЕНОКАРЦИНОМА -- ADENOCARCINOMA (диагностика, смертность, терапия) Анотація: The aim of the study was assessment of survival dynamics of ovarian cancer. The survey was conducted on the basis of OOD (c, Odessa) for2010 - 2015 were examined350patients with ovarian adenocarcinoma of Ill-IV stage, which was carried with cytoreduction surgery. The average age of patients was 55,3 ± 3,9 years. The sample was dominated by patients with stage IIIC - on average there were 64.9% of the total sample. It is shown that the introduction of integrated circuits based pathogenesis of drug therapy with considering the platinum-resistance can significantly prolong the survival of patients with ovarian cancer. Pathogenetic therapy based on pharmacogenetic peculiarities can significantly improve treatment outcomes (up to 33,1 ± 1,4 months in patients likely to platinum resistance and 36,8 ± 1,9 months in platinum sensitive cases). If probable platynorezystentnosti advisable due to the standard first- line therapy drug use dyzrehulyatsiynyh adjustment disorders (donors of nitric oxide, detoxicant, antyurykemichni means). With predictable platinum sensitivity the standard first- line treatment can be supplemented with medications improving tolerance to, but the use of the medications for correction of disregulatory disorders is inappropriate Дод.точки доступу: Svintsitsky, V. S. Вільних прим. немає